chidamide

Chidamide (also known as tucidinostat or cedarbezine) is an orally bioavailable, selective histone deacetylase (HDAC) inhibitor developed by Chipscreen Biosciences. It specifically targets Class I HDACs (HDAC1, HDAC2, HDAC3) and Class IIb HDAC (HDAC10), leading to increased histone acetylation and the modulation of gene expression involved in cell cycle arrest, apoptosis, and immune surveillance. Chidamide was the first HDAC inhibitor approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and has since received approval for hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane. It is also being investigated in various other hematological malignancies, such as acute T-lymphoblastic leukemia (T-ALL) and diffuse large B-cell lymphoma (DLBCL), often as part of multi-target combination regimens.

Brand names

Epidaza

Other names

cedarbezinetucidinostatXidaben'an西达本胺